Baird Capital Portfolio Company GenomeDx Biosciences Highlighted in Forbes

Baird Capital portfolio company GenomeDx Biosciences was recently featured in a Forbes story on the company’s Decipher Prostate Cancer Test and advancements in genetic testing.

Read the full article.